Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PFE with free AI briefings, catalyst countdowns, and dilution alerts.

PFE · Pfizer Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11B Cash on Hand
CF+ Cash Runway
2.4% Short Interest
$30.22 Analyst Target (26)
Follow PFE by email Get an email when PFE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PFE, unsubscribe in one click. Privacy

📣 What PFE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Marstacimab
FDA approved Oct 2024 · Hympavzi
Hemophilia A or B Phase 3 · NCT07923981 Recruiting
Palbociclib
FDA approved Feb 2015 · Ibrance
HPV-unrelated Head and Neck Squamous Cell Carcinoma Phase 3 · NCT04966481 Recruiting
Abrocitinib
FDA approved Jan 2022 · Cibinqo
Eczema Phase 3 · NCT06807268 Active not recruiting
Tucatinib
FDA approved Apr 2020 · Tukysa
Colorectal Neoplasms Phase 3 · NCT05253651 Active not recruiting
Elranatamab
FDA approved Aug 2023 · Elrexfio
Multiple Myeloma Phase 3 · NCT06152575 Recruiting
Bortezomib
FDA approved May 2022 · Bortezomib
Multiple Myeloma Phase 3 · NCT06152575 Recruiting
Etrasimod
FDA approved Oct 2023 · Velsipity
Ulcerative Colitis Phase 3 · NCT03950232 Active not recruiting
Tisotumab Vedotin
FDA approved Sep 2021 · Tivdak
Vulvar Carcinoma Phase 2 · NCT07672782 Not yet recruiting
Somatrogon
FDA approved Jun 2023 · Ngenla
Dwarfism, Pituitary N/A · NCT06587035 Recruiting
Lorlatinib
FDA approved Nov 2018 · Lorbrena
Non-Small-Cell Lung N/A · NCT07567352 Active not recruiting
Fordadistrogene Movaparvovec Duchenne Muscular Dystrophy Phase 3 · NCT05689164 Terminated
Giredestrant Early Breast Cancer Phase 3 · NCT07890597 Not yet recruiting
Intra-articular corticosteroid injections Oligoarthritis, Juvenile Phase 3 · NCT03728478 Active not recruiting
PG4 Multivalent Vaccine Pneumococcal Disease Phase 3 · NCT07794748 Active not recruiting
RSVpreF (Regimen A) Respiratory Syncytial Virus (RSV) Phase 3 · NCT07839871 Recruiting
Sigvotatug Vedotin Non-Small Cell Lung Cancer Phase 3 · NCT06758401 Recruiting

Also used in these trials (approved or third-party drugs, not PFE's own candidates): Pembrolizumab, Leucovorin, Levoleucovorin Calcium, Methotrexate, Oxaliplatin, Pomalidomide, Ritlecitinib, Trastuzumab, Dexamethasone, Cetuximab, Carfilzomib, Elotuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PFE holds $11B in cash and short-term investments (as of Sep 27, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PFE files for a raise →

👥 Who Owns PFE

Insiders 0% Other 5%+ holders 0.4% Institutions (3731 holders) 69.3% Public and other holders 30.3%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 521,032,629 9.14% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 427,444,872 7.50% 2026-03-31
State Street Corporation Institution (13F) 309,573,847 5.43% 2026-09-30
Geode Capital Management, LLC Institution (13F) 137,506,393 2.41% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 120,474,634 2.11% 2026-09-30
Fisher Asset Management, LLC Institution (13F) 112,118,836 1.97% 2026-09-30
Morgan Stanley Institution (13F) 96,931,707 1.70% 2026-09-30
Massachusetts Financial Services Co. Institution (13F) 64,605,278 1.13% 2026-09-30
Northern Trust Corporation Institution (13F) 58,902,014 1.03% 2026-09-30
Pfizer Inc. 5%+ holder (13D) 22,032,040 0.39% 2025-11-06
PFIZER INC. (13-5315170) 5%+ holder (13G) 1,965,066 0.03% 2026-10-08
Albert Bourla
Chairman & CEO, Director · +795,823 options
Insider 435,555 0.01% 2026-08-12

Share count 5,699,853,733 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-13
filed 2026-11-16
BOURLA ALBERT
Option award (A) 21 $28.89 –
2026-10-30
filed 2026-11-03
BOURLA ALBERT
Option award (A) 20 $30.52 –
2026-10-15
filed 2026-10-16
BOURLA ALBERT
Option award (A) 20 $29.44 –
2026-10-13
filed 2026-10-14
BOURLA ALBERT
Option award (A) 71 $28.37 –
2026-09-30
filed 2026-10-01
BOURLA ALBERT
Option award (A) 21 $28.52 –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full PFE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PFE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.